SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
"I think it's important that we notice here that we the public, we the people, developed this drug, we paid for this drug," Rep. Alexandria Ocasio-Cortez (D-N.Y.) said during a House Oversight and Reform Committee on Thursday. (Photo: Alex Brandon/AP)
'Spoiler: Because Australia Has Universal Healthcare': Watch Ocasio-Cortez Ask Pharma CEO Why HIV Drug Costs $8 Overseas But $1,780 in the US
"We the public, we the people, developed this drug, we paid for this drug. There's no reason this should be $2,000 a month. People are dying because of it."
May 16, 2019
During a House hearing on Thursday, Rep. Alexandria Ocasio-Cortez asked the CEO of one of America's largest pharmaceutical companies a simple but crucial question: Why does a life-saving HIV drug that costs $8 a month in Australia have a $2,000 price tag in the U.S.?
Gilead chief executive Daniel O'Day declined to comment on the low price of Truvada for PrEP in Australia, but said the reason the cost is close to $2,000--"the current list price is $1,780," he said--in the United States is because the drug has "patent protection."
As the Washington Post reported in March, the development of Truvada as a treatment for HIV was "almost fully funded by U.S. taxpayers."
The U.S. government patented the treatment in 2015, according to the Post, but has "opted not to file an infringement suit to enforce" the patent even as Gilead--which argues the government patent is invalid--rakes in billions of dollars in profits from Truvada.
Ocasio-Cortez highlighted these facts during the House Oversight and Reform Committee hearing on Thursday.
"I think it's important that we notice here that we the public, we the people, developed this drug, we paid for this drug, we led and developed all of the grounding patents to create PrEP, and then that patent has been privatized despite the fact that that patent is owned by the public," said Ocasio-Cortez. "We refuse to enforce it."
"There's no reason this should be $2,000 a month," Ocasio-Cortez added. "People are dying because of it. We own the intellectual property for it. People are dying for no reason. For no reason. We developed this drug."
In a tweet following Thursday's hearing, Ocasio Cortez answered her own question on why Truvada's price is $8 in Australia.
"Spoiler: Because Australia has universal healthcare," wrote the New York congresswoman.
The reason the United States hasn't joined the rest of the industrialized world in establishing a universal healthcare system is not individual drug company executives like O'Day, said Ocasio-Cortez.
"I don't blame you. I blame us. I blame this body," Ocasio-Cortez said during the hearing. "Because every single developed country in the world guarantees healthcare as a right except us. Except the United States. Because we can't get it together. Because we don't have the fortitude to kick pharmaceutical lobbyists [out of] our congressional offices."
\u201c.@RepAOC @AOC: "I blame us. I blame this body because every single developed country in the world guarantees health care as a right except us, except the United States, because we can't get it together."\u201d— CSPAN (@CSPAN) 1558029458
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
During a House hearing on Thursday, Rep. Alexandria Ocasio-Cortez asked the CEO of one of America's largest pharmaceutical companies a simple but crucial question: Why does a life-saving HIV drug that costs $8 a month in Australia have a $2,000 price tag in the U.S.?
Gilead chief executive Daniel O'Day declined to comment on the low price of Truvada for PrEP in Australia, but said the reason the cost is close to $2,000--"the current list price is $1,780," he said--in the United States is because the drug has "patent protection."
As the Washington Post reported in March, the development of Truvada as a treatment for HIV was "almost fully funded by U.S. taxpayers."
The U.S. government patented the treatment in 2015, according to the Post, but has "opted not to file an infringement suit to enforce" the patent even as Gilead--which argues the government patent is invalid--rakes in billions of dollars in profits from Truvada.
Ocasio-Cortez highlighted these facts during the House Oversight and Reform Committee hearing on Thursday.
"I think it's important that we notice here that we the public, we the people, developed this drug, we paid for this drug, we led and developed all of the grounding patents to create PrEP, and then that patent has been privatized despite the fact that that patent is owned by the public," said Ocasio-Cortez. "We refuse to enforce it."
"There's no reason this should be $2,000 a month," Ocasio-Cortez added. "People are dying because of it. We own the intellectual property for it. People are dying for no reason. For no reason. We developed this drug."
In a tweet following Thursday's hearing, Ocasio Cortez answered her own question on why Truvada's price is $8 in Australia.
"Spoiler: Because Australia has universal healthcare," wrote the New York congresswoman.
The reason the United States hasn't joined the rest of the industrialized world in establishing a universal healthcare system is not individual drug company executives like O'Day, said Ocasio-Cortez.
"I don't blame you. I blame us. I blame this body," Ocasio-Cortez said during the hearing. "Because every single developed country in the world guarantees healthcare as a right except us. Except the United States. Because we can't get it together. Because we don't have the fortitude to kick pharmaceutical lobbyists [out of] our congressional offices."
\u201c.@RepAOC @AOC: "I blame us. I blame this body because every single developed country in the world guarantees health care as a right except us, except the United States, because we can't get it together."\u201d— CSPAN (@CSPAN) 1558029458
During a House hearing on Thursday, Rep. Alexandria Ocasio-Cortez asked the CEO of one of America's largest pharmaceutical companies a simple but crucial question: Why does a life-saving HIV drug that costs $8 a month in Australia have a $2,000 price tag in the U.S.?
Gilead chief executive Daniel O'Day declined to comment on the low price of Truvada for PrEP in Australia, but said the reason the cost is close to $2,000--"the current list price is $1,780," he said--in the United States is because the drug has "patent protection."
As the Washington Post reported in March, the development of Truvada as a treatment for HIV was "almost fully funded by U.S. taxpayers."
The U.S. government patented the treatment in 2015, according to the Post, but has "opted not to file an infringement suit to enforce" the patent even as Gilead--which argues the government patent is invalid--rakes in billions of dollars in profits from Truvada.
Ocasio-Cortez highlighted these facts during the House Oversight and Reform Committee hearing on Thursday.
"I think it's important that we notice here that we the public, we the people, developed this drug, we paid for this drug, we led and developed all of the grounding patents to create PrEP, and then that patent has been privatized despite the fact that that patent is owned by the public," said Ocasio-Cortez. "We refuse to enforce it."
"There's no reason this should be $2,000 a month," Ocasio-Cortez added. "People are dying because of it. We own the intellectual property for it. People are dying for no reason. For no reason. We developed this drug."
In a tweet following Thursday's hearing, Ocasio Cortez answered her own question on why Truvada's price is $8 in Australia.
"Spoiler: Because Australia has universal healthcare," wrote the New York congresswoman.
The reason the United States hasn't joined the rest of the industrialized world in establishing a universal healthcare system is not individual drug company executives like O'Day, said Ocasio-Cortez.
"I don't blame you. I blame us. I blame this body," Ocasio-Cortez said during the hearing. "Because every single developed country in the world guarantees healthcare as a right except us. Except the United States. Because we can't get it together. Because we don't have the fortitude to kick pharmaceutical lobbyists [out of] our congressional offices."
\u201c.@RepAOC @AOC: "I blame us. I blame this body because every single developed country in the world guarantees health care as a right except us, except the United States, because we can't get it together."\u201d— CSPAN (@CSPAN) 1558029458
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.